DPP4 and Other metabolic disease: It is also unknown how much of resistance of endogenous signaling contributes to the heterogeneity observed in metabolic disease and the variable patient responses to pharmacological treatments including DPP4 inhibitors, GLP-1R agonists and bariatric surgery.